DVAX Dynavax Technologies Corporation

-0.15  -4%
Previous Close 3.8
Open 3.81
Price To Book 5.53
Market Cap 237,494,346
Shares 65,066,944
Volume 1,037,409
Short Ratio
Av. Daily Volume 1,337,207

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced May 23, 2019 that it will discontinue investment in this program.
SD-101 + Pembrolizumab
Melanoma and head and neck squamous cell carcinoma (HNSCC)
CRL February 25, 2013 and November 14, 2016. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval. Final approval announced November 9, 2017.
Hepatitis B
Phase 2a trial did not meet primary endpoint - November 29, 2018.
Announced May 23, 2019 that it will discontinue investment in this program.
Non-small Cell Lung Cancer (NSCLC)
Phase 1 commencement of enrolment announced May 2, 2019.
End Stage Renal Disease on Dialysis

Latest News

  1. Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference  
  2. Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting
  3. Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
  4. Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
  5. The Week Ahead In Biotech: ASCO Presentations In The Spotlight
  6. Here's Why Dynavax Technologies Is Tumbling
  7. East Bay biotech pivoted to cancer, found new space — now CEO is leaving, 82 jobs are cut
  8. The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice
  9. Dynavax announces layoffs, CEO retirement
  10. Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business
  11. Could The Dynavax Technologies Corporation (NASDAQ:DVAX) Ownership Structure Tell Us Something Useful?
  12. Edited Transcript of DVAX earnings conference call or presentation 8-May-19 8:30pm GMT
  13. Hopeful Signs for These 2 Small Biotech Stocks
  14. Why Dynavax Technologies Stock Is Soaring Today
  15. Is Dynavax Technologies Corporation (DVAX) A Good Stock To Buy?
  16. Dynavax Technologies Corp (DVAX) Q1 2019 Earnings Call Transcript
  17. Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
  18. Dynavax Technologies: 1Q Earnings Snapshot
  19. Dynavax Announces First Quarter 2019 Financial Results
  20. Dynavax Technologies Corp. to Host Earnings Call